Pseudoephedrine
| Evidence Level: L5 | Predicted Indications: 2 |
Table of Contents
- Pseudoephedrine
- Pharmacist Assessment Report
- Pseudoephedrine: Nasal cavity disease
- One-Sentence Summary
- Quick Overview
- Why is This Prediction Reasonable?
- Clinical Trial Evidence
- Literature Evidence
- Australia Market Information
- Safety Considerations
- Other Predicted Indications (Brief)
- Conclusion and Next Steps
- Disclaimer
Pseudoephedrine: Nasal cavity disease
One-Sentence Summary
Pseudoephedrine is an oral sympathomimetic decongestant, originally used for allergic rhinitis, the common cold and related upper airway conditions. The TxGNN model predicts it may be effective for nasal cavity disease, but this largely overlaps with its existing use. There are no registered clinical trials and 7 publications for this prediction, mostly reviews and animal models.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not recorded in the local data |
| Predicted New Indication | Nasal cavity disease |
| TxGNN Prediction Score | 0.9975 |
| Evidence Level | L5 |
| Australia Market Status | Listed on the PBS Schedule (1 of 1 items) – TGA (ARTG) registration status is not included in this data |
| Number of PBS Items | 1 (valid: 1) |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism of action data is not available in the data compiled for this report. Based on known pharmacology, pseudoephedrine is an indirect sympathomimetic with alpha-adrenergic activity. It constricts blood vessels in the nasal mucosa and relieves congestion. This is the basis of its existing rhinitis and common cold uses.
Nasal cavity disease is a broad category that largely overlaps with these approved uses. The prediction therefore mostly restates the current indication rather than identifying a genuinely new one. The supporting literature is a review of nonallergic rhinitis, a comparison of oral and topical decongestant effects (phenylpropanolamine vs d-pseudoephedrine), and several dog and cat models of nasal congestion.
Clinical Trial Evidence
Currently no related clinical trials registered for nasal cavity disease.
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 11345158 | 2001 | Clinical pharmacology study | Am J Rhinol | Compared the nasal decongestant effects of oral phenylpropanolamine and d-pseudoephedrine using acoustic rhinometry |
| 22794679 | 2012 | Review | Allergy Asthma Proc | Overview of nonallergic rhinitis, covering inflammatory and noninflammatory causes |
| 19769798 | 2009 | Animal model | Am J Rhinol Allergy | Loratadine and montelukast combination produced decongestion in a feline model; pseudoephedrine was also studied as a decongestant |
| 24492651 | 2014 | Animal model | J Pharmacol Exp Ther | Selective α2c-adrenergic agonists evaluated in animal models of nasal congestion |
| 12962193 | 2003 | Animal model | Am J Rhinol | Model of allergic nasal congestion in ragweed-sensitised dogs |
| 12387934 | 2002 | Animal model | J Pharmacol Toxicol Methods | Pharmacological characterisation of a chronic dog model of nasal congestion |
| 11895194 | 2002 | Animal model | Am J Rhinol | Acoustic rhinometry in dogs as a model for nasal congestion studies |
Australia Market Information
| ARTG Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| ARTG 4029C | Pharmacy Action Sinus & Nasal Decongestant Relief | Tablet 60 mg (oral) | Not available in the data compiled for this report |
Safety Considerations
Contraindications flagged by the knowledge graph (not label text): hypertension, coronary artery disease, congestive heart failure, stroke and cerebrovascular disorders, hypotensive disorder, diabetes mellitus and diabetic ketoacidosis, hypothyroidism, epilepsy, COPD, kidney disease, liver disease and liver failure, peptic ulcer disease and gastric ulcer, inflammatory bowel disease, pancreatitis, gallbladder disease, benign prostatic hyperplasia, blood coagulation disease, substance abuse/dependence, and rhabdomyolysis, among others.
Drug Interactions: 100 interactions were identified. The ones reviewed are mostly Moderate, with one Minor (ascorbic acid). They are largely with antidiabetic agents:
- Sulfonylureas: acetohexamide, chlorpropamide, glimepiride, glipizide, glyburide
- SGLT2 inhibitors: canagliflozin, dapagliflozin, empagliflozin, ertugliflozin
- GLP-1 agonists and DPP-4 inhibitors: albiglutide, dulaglutide, exenatide, alogliptin
- Insulins and acarbose
- Diethylpropion (a sympathomimetic appetite suppressant)
Please refer to the TGA-approved Product Information (PI) for official warnings and contraindications, as label data were not available.
Other Predicted Indications (Brief)
| Rank | Predicted Indication | Score | Evidence Level | Comment |
|---|---|---|---|---|
| 3 | Allergic urticaria | 0.9914 | L4 | Literature concerns antihistamines, not pseudoephedrine |
Conclusion and Next Steps
Decision: Hold
Rationale: The top prediction (nasal cavity disease) mostly overlaps with pseudoephedrine’s existing approved use, and its support is indirect or preclinical (L4). It does not represent a true new indication. The other predictions have no evidence or only weak, indirect evidence.
To proceed, the following is needed:
- Mechanism of action data and the TGA Product Information warnings and contraindications (a blocking gap for safety screening)
- Confirmation of the approved indication text for the ARTG entry
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.